Minerva Neurosciences (NERV) AI Stock Analysis

• Market Cap: $336.67M
• Dividend Yield: N/A
• Average Volume (3M): 465.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: N/A
• EPS Growth: -323.61%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.64
• Shares Outstanding: 43,274,400
• 10 Day Avg. Volume: 1,362,901
• 30 Day Avg. Volume: 465,600
• PEG Ratio: <0.01
• Price to Book (P/B): -0.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 0.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -13.58K
• Enterprise Value/Ebitda: -3.37
• 1Y Price Target: $7.00
• Price Target Upside: -10.03% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.79
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $7.50 ▼(-3.60% Downside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is held down primarily by very weak financial performance (no revenue, persistent losses, heavy cash burn, and negative equity). Technical momentum is a notable offset, while valuation remains challenged due to ongoing losses. Corporate updates are somewhat supportive, but emphasize the need for future financing.

Positive Factors

Low leverage

Minimal debt reduces refinancing and interest-service risk for a clinical-stage biotech with no product revenue. This durable balance-sheet trait preserves management optionality to prioritize R&D and seek equity or partnerships to fund trials without immediate debt constraints.

Clear Phase 3 plan & FDA alignment

A defined, FDA-aligned confirmatory Phase 3 with set enrollment, endpoints and timelines (topline H2 2027, relapse H2 2028) materially lowers regulatory execution risk versus ambiguous plans. That clarity improves strategic planning and partner or investor assessment over the next 2–3 years.

Expanded capital & governance flexibility

Broader authorized shares, an enlarged equity incentive pool, and governance approvals increase the company’s structural ability to raise financing and grant incentives to retain talent. This enhances long-term funding flexibility to advance clinical programs, albeit at dilution risk.

Negative Factors

No revenue; persistent losses

Multiple years of zero product revenue and ongoing operating losses mean the company cannot self-fund operations or trials. Reliance on external financing is structural, reducing margin of safety and increasing execution risk if capital markets tighten or investor appetite wanes over the 2–6 month horizon and beyond.

Negative shareholders' equity

Negative equity reflects a weakened capital base and can limit financing options, increase cost of capital, and heighten dilution when capital is raised. This structural balance-sheet weakness constrains strategic flexibility and raises solvency and covenant sensitivity over time.

Poor cash generation & high burn

Sustained negative operating and free cash flows with volatile year-to-year results create ongoing funding gaps. Without revenue, the company depends on financings to complete pivotal trials; this persistent burn increases execution and dilution risk and can delay programs if capital is insufficient.

Minerva Neurosciences Business Overview & Revenue Model

Company Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

As a clinical-stage biotechnology company, Minerva Neurosciences has historically not generated significant recurring revenue from product sales because it has not had an approved, commercialized drug. Its operations have primarily been funded through financing activities (such as public offerings of equity and, where applicable, other capital-raising transactions). Information on specific, consistent revenue streams from licensing, collaboration payments, royalties, or product revenue is null.

Minerva Neurosciences Financial Statement Overview

Summary

Financial performance is very weak: revenue has been $0 for multiple years, operating losses persist, cash flow is consistently negative with significant burn, and stockholders’ equity is negative despite low debt—creating elevated funding and dilution risk.

Income Statement

The income statement is very weak: revenue has been $0 from 2021–2025 (annual), with persistent operating losses and large net losses in most years. While 2024 showed a small net profit, profitability is not durable given continued operating losses and the return to a very large net loss in 2025. Overall visibility into a sustainable earnings engine is limited without recurring revenue.

Balance Sheet

Leverage is low (total debt is effectively $0 in recent years), which is a positive. However, stockholders’ equity is negative from 2022–2025 (annual), a major balance-sheet weakness that can constrain financing flexibility and increases dilution/solvency risk. Total assets have also trended down versus earlier periods, reinforcing the weakened capital base.

Cash Flow

Cash generation is poor, with consistently negative operating cash flow and free cash flow across all years shown. The scale of cash burn is significant (including a very large outflow in 2025), and year-to-year free cash flow growth is volatile, reflecting instability rather than improvement. With ongoing cash outflows and no revenue base, funding needs likely remain elevated.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-5.44K	0.00	0.00	0.00	0.00
EBITDA	-15.10M	6.02M	-21.69M	-24.69M	-45.28M
Net Income	-293.42M	1.44M	-30.01M	-32.11M	-49.91M
Balance Sheet
Total Assets	97.97M	37.14M	56.90M	55.09M	77.12M
Cash, Cash Equivalents and Short-Term Investments	82.30M	21.36M	40.91M	36.09M	60.76M
Total Debt	64.96M	0.00	0.00	0.00	0.00
Total Liabilities	233.75M	62.84M	85.36M	75.11M	69.15M
Stockholders Equity	-140.75M	-25.69M	-28.46M	-20.02M	7.98M
Cash Flow
Free Cash Flow	-13.51B	-19.55M	-14.78M	-24.66M	-24.60M
Operating Cash Flow	-13.51B	-19.55M	-14.78M	-24.65M	-24.60M
Investing Cash Flow	0.00	0.00	0.00	-16.33K	0.00
Financing Cash Flow	74.45B	0.00	19.60M	-5.00	60.00M

Minerva Neurosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NERV, the sentiment is Positive. The current price of 7.78 is above the 20-day moving average (MA) of 6.95, above the 50-day MA of 5.66, and above the 200-day MA of 3.48, indicating a bullish trend. The MACD of 0.63 indicates Negative momentum. The RSI at 65.24 is Neutral, neither overbought nor oversold. The STOCH value of 71.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NERV.

Minerva Neurosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NERV	49 Neutral	$336.67M	-0.12	―	―	―	-323.61%
BLRX	48 Neutral	$11.79M	-3.82	-22.03%	―	-41.76%	87.36%
PULM	43 Neutral	$7.56M	-1.58	-79.47%	―	-99.97%	35.59%
CMMB	39 Underperform	$12.31M	-2.33	-89.92%	―	―	53.19%

Minerva Neurosciences Corporate Events

Minerva Outlines Confirmatory Phase 3 Plan for Roluperidone

Minerva Neurosciences announced that at a virtual key opinion leader event held on February 3, 2026, it would provide additional details on its proposed confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms in schizophrenia. The company outlined plans to initiate the trial in the second quarter of 2026, enrolling 380 patients randomized to receive either placebo or a once-daily 64 mg dose of roluperidone, with a primary efficacy endpoint based on change from baseline in PANSS Marder negative symptoms factor score at 12 weeks, followed by a 40-week relapse assessment phase in which patients will crossover to receive either roluperidone or antipsychotics, with topline efficacy data expected in the second half of 2027 and relapse assessment results anticipated in the second half of 2028, underscoring Minerva’s continued effort to advance a potential first-in-class treatment for an area of significant unmet need in schizophrenia care.

The most recent analyst rating on (NERV) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.

Minerva Neurosciences Shareholders Approve Key Governance Measures

At its annual meeting of stockholders held on December 22, 2025, Minerva Neurosciences, Inc. secured broad shareholder approval for a series of measures expanding its equity and capital flexibility, including an amendment to its 2013 Equity Incentive Plan to add 12,500,000 shares for potential issuance. Stockholders re-elected two directors to terms running until the 2028 annual meeting, approved doubling the company’s authorized common shares from 125 million to 250 million, authorized the issuance of common stock upon conversion of Series A Convertible Voting Preferred Stock in line with Nasdaq rules, endorsed executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025, collectively reinforcing management’s governance, financing capacity and incentive structures.

The most recent analyst rating on (NERV) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.